GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: GSK2831781
Drug: Placebo

First Posted Date: 2019-05-29

Last Posted Date: 2020-11-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT03965533

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Other: Prospective observational cohort study

First Posted Date: 2019-05-21

Last Posted Date: 2024-02-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 70

Registration Number: NCT03957577

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

Phase 3

Completed

Conditions: Infections, Rotavirus

Interventions: Biological: Lyophilized formulation of GSK's oral live attenuated HRV vaccine
Biological: PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine

First Posted Date: 2019-05-17

Last Posted Date: 2022-03-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1351

Registration Number: NCT03954743

Locations: 🇹🇷
GSK Investigational Site, Kayseri, Turkey

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

Phase 4

Withdrawn

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists
Drug: Fluticasone furoate/umeclidinium/vilanterol

First Posted Date: 2019-05-14

Last Posted Date: 2020-04-22

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT03949842

Locations: 🇺🇸
GSK Investigational Site, Layton, Utah, United States

Study to Characterize the Efficacy of a Dual Active Dentifrice for the Relief of Dentin Hypersensitivity

Phase 2

Completed

Conditions: Dentin Sensitivity
Dentin Hypersensitivity

Interventions: Other: Potassium Nitrate
Other: Stannous Fluoride

First Posted Date: 2019-05-09

Last Posted Date: 2020-09-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 123

Registration Number: NCT03943095

Locations: 🇨🇦
GSK Investigational Site, Mississauga, Canada

Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine

Phase 2

Completed

Conditions: Respiratory Disorders

Interventions: Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E
Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)

First Posted Date: 2019-03-29

Last Posted Date: 2022-06-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 541

Registration Number: NCT03894969

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

Phase 2

Terminated

Conditions: Colitis, Ulcerative

Interventions: Drug: GSK2831781 - Double Blind Phase
Drug: Placebo
Drug: GSK2831781 - Open Label phase

First Posted Date: 2019-03-28

Last Posted Date: 2022-04-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 104

Registration Number: NCT03893565

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects

Phase 1

Terminated

Conditions: Leishmaniasis

Interventions: Drug: GSK3186899
Drug: Placebo

First Posted Date: 2019-03-14

Last Posted Date: 2023-02-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 25

Registration Number: NCT03874234

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Phase 1

Terminated

Conditions: Hepatitis B, Chronic

Interventions: Biological: ChAd155-hIi-HBV high dose formulation
Biological: ChAd155-hIi-HBV low dose formulation
Drug: Placebo
Biological: HBc-HBs/AS01B-4 low dose formulation
Biological: HBc-HBs/AS01B-4 high dose formulation
Biological: MVA-HBV high dose formulation
Biological: MVA-HBV low dose formulation

First Posted Date: 2019-03-07

Last Posted Date: 2024-11-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 135

Registration Number: NCT03866187

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa

Recruiting

Conditions: Malaria
Malaria Vaccines

Interventions: Procedure: Whole blood sample

First Posted Date: 2019-02-27

Last Posted Date: 2025-02-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 78000

Registration Number: NCT03855995

Locations: 🇲🇼
GSK Investigational Site, Mangochi, Malawi

Home Terms & Conditions Privacy Policy